PRIMARY PERITONEAL CANCER

This completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel …

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…

This study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer…

This study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that stopped responding to platinum chemotherapy and had previously taken PARP inhibitors. The goal was to see if the combo could control the cancer for at least 6 months. The…

This study tested a new drug called IMP4297 in 93 women with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has come back after at least two prior treatments. The goal was to see if the drug can shrink tumors or slow the cancer's growth. The drug is taken as …

This phase 2 trial tested a drug called mirvetuximab soravtansine in 79 people with recurrent platinum-sensitive ovarian, peritoneal, or fallopian tube cancers that have high levels of a protein called folate receptor-alpha. The drug is given by IV every three weeks. The main goa…

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 alone could shrink tumors and how safe it was. Participants had already tried at least three other…

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This pilot study tested whether adding the immunotherapy drugs nivolumab (with or without ipilimumab) to standard chemotherapy could be safe for people with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. 27 participants received the drug combina…

This study tested whether zafirlukast, an asthma drug, can slow or stop ovarian cancer in people whose only sign of relapse is a rising CA-125 blood marker. Only 5 participants were enrolled. The main goal was to see if the drug could lower CA-125 levels by at least half for a mo…

This phase 2 trial tested whether adding an experimental drug (MK-4830) to standard chemotherapy and pembrolizumab (Keytruda) could better shrink high-grade serous ovarian cancer before surgery. 160 participants with stage III or IV disease received either the standard regimen or…

This study looked at whether a 10-week pelvic physical therapy program is practical for gynecologic cancer survivors who have sexual problems. Twenty survivors were enrolled to see if they could stick with the program and if it improved their sexual function and quality of life. …

This study tested a mobile app designed to help doctors keep track of symptoms in women with advanced ovarian cancer. Ten patients used the app, which combined their medical records with regular symptom reports. The goal was to see if this information helped the care team make be…

This study looks at proteins in the blood of women with ovarian, peritoneal, or fallopian tube cancer who are in remission. The goal is to find a protein pattern, or 'fingerprint,' that signals when the cancer might come back. Researchers followed 119 women with stage III or IV c…

This study looked at how doctors in Russia treat a specific type of ovarian cancer called HRD-positive. Researchers collected information from 414 patients to understand what treatments they received and how they fared. The goal was to describe real-world practice, not to test a …

This study looked back at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as maintenance therapy. Researchers wanted to see how often serious side effects happened and how patients used the drug in real-life UK clinics. No …

This study looked at whether following national guidelines for ovarian cancer surgery is cost-effective. Researchers measured the cost per quality-adjusted life year (QALY) over three years in 200 women with advanced ovarian cancer. The goal was to understand the economic impact …

This study reviewed medical records of 51 women with ovarian, fallopian tube, or peritoneal cancer who received the drug rucaparib in real-world clinics, not just in strict trials. Researchers looked at patient history, side effects, dosing, and how long the drug kept cancer from…

This study looked at whether it's possible to give ovarian cancer patients a special nutrition shake for seven days before their surgery. 23 patients took part to see if they would stick with the program. The goal was just to see if the program was doable, not to measure health b…